A performance comparison of two (electro) chemiluminescence immunoassays for detection and quantitation of serum anti‐spike antibodies according to SARS‐CoV‐2 vaccination and infections status
暂无分享,去创建一个
E. Albert | E. Giménez | D. Navarro | R. Geller | B. Olea | M. Alcaráz | Jorge Camacho | Joao Zulaica | Beatriz Álvarez-Rodríguez | Luciana Rusu
[1] R. Bull,et al. Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission , 2022, Reviews in medical virology.
[2] J. Swadzba,et al. Head-to-Head Comparison of 5 Anti-SARS-CoV-2 Assays Performance in One Hundred COVID-19 Vaccinees, over an 8-Month Course , 2022, Diagnostics.
[3] G. Lippi,et al. Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization , 2022, Vaccines.
[4] Hejun Liu,et al. Protective neutralizing epitopes in SARS‐CoV‐2 , 2022, Immunological reviews.
[5] M. Tormo,et al. SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders , 2022, Journal of Hematology & Oncology.
[6] H. Einsele,et al. Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9) , 2022, Leukemia.
[7] M. Davenport,et al. Disentangling the relative importance of T cell responses in COVID-19: leading actors or supporting cast? , 2022, Nature Reviews Immunology.
[8] E. Theel,et al. Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It? , 2022, Journal of clinical microbiology.
[9] Jared G. Galloway,et al. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection , 2022, eLife.
[10] E. Albert,et al. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents , 2021, Scientific Reports.
[11] Lindsay N. Carpp,et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial , 2021, Science.
[12] M. Davenport,et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis , 2021, The Lancet Microbe.
[13] D. Giavarina,et al. Comparison of Anti–SARS-CoV-2 S1 Receptor-Binding Domain Antibody Immunoassays in Health Care Workers Before and After the BNT162b2 mRNA Vaccine , 2021, American journal of clinical pathology.
[14] M. Rabilloud,et al. Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated healthcare workers. , 2021, medRxiv.
[15] K. Park,et al. Performance evaluation of three automated quantitative immunoassays and their correlation with a surrogate virus neutralization test in coronavirus disease 19 patients and pre‐pandemic controls , 2021, Journal of clinical laboratory analysis.
[16] G. B. Karlsson Hedestam,et al. Immunity to SARS‐CoV‐2 induced by infection or vaccination , 2021, Journal of internal medicine.
[17] G. Jakiel,et al. Usefulness of IVD Kits for the Assessment of SARS-CoV-2 Antibodies to Evaluate the Humoral Response to Vaccination , 2021, Vaccines.
[18] T. Koller,et al. Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays , 2021, Microbiology spectrum.
[19] Patrick W. Johnson,et al. SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods , 2021, Journal of clinical microbiology.
[20] J. Vekemans,et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[21] J. Bloom,et al. Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection , 2021, Science Translational Medicine.
[22] M. Davenport,et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.
[23] G. Lippi,et al. Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA , 2021, Journal of medical biochemistry.
[24] V. Kulasingam,et al. Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation , 2021, Journal of Clinical Microbiology.
[25] E. Albert,et al. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays , 2020, European Journal of Clinical Microbiology & Infectious Diseases.
[26] Mei San Tang,et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays , 2020, bioRxiv.
[27] Christa Boer,et al. Correlation Coefficients: Appropriate Use and Interpretation , 2018, Anesthesia and analgesia.
[28] L. Myers,et al. Spearman Correlation Coefficients, Differences between , 2004 .
[29] D. Pfeffermann,et al. Small area estimation , 2011 .